ClinicalTrials.gg
CompletedNCT00431132Updated Mar 15, 2017Results posted

Endometrial Safety of a Low Dose of Vagifem® in Postmenopausal Women With Atrophic Vaginitis

A Phase 3 interventional study of estradiol, 10 mcg in Menopause and Postmenopausal Vaginal Atrophy, sponsored by Novo Nordisk A/S. Completed at 42 sites in 7 countries. Open to female participants aged 45 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-03-15.

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
336
Allocation
Non-randomized
Ages
45 Years and older
Sex
Female
01

Study summary

This trial is conducted in Europe. The purpose of this study is to evaluate endometrial safety of intravaginal estradiol (Vagifem®) in healthy postmenopausal women having atropic vaginitis.

02

Conditions studied

  • Menopause
  • Postmenopausal Vaginal Atrophy
03

In context

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
45 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • women whose last menstruation was at least two years prior to the time of screening
  • At least 1 urogenital symptom (vaginal dryness, vaginal and/or vulvar irritation/itching, vaginal soreness, dysuria, dyspareunia and vaginal bleeding associated with sexual activity
  • Generally healthy

Exclusion criteria

Exclusion Criteria:

  • Exposure to exogenous sex hormones (estrogen and/or progestin hormone replacement therapy) within past 3 months
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
336 participants (actual)

Study arms

  • Experimental
    Vagifem® 10 mcg

    One 10 mcg (microgram) vaginal tablet of intravaginal estradiol (Vagifem®) once daily for two weeks followed by one 10 mcg vaginal tablet twice weekly for 50 weeks

    Drug: estradiol, 10 mcg

Interventions

06

What researchers measure

Primary outcomes

  1. Endometrial Hyperplasia Based on Histological Assessment of Endometrial Biopsies

    The endometrial hyperplasia rate was calculated based on the number of patients with endometrial hyperplasia/endometrial carcinoma divided by the total number of subjects with interpretable biopsies at Week 52.

    Time frame: Week 52

Secondary outcomes

  1. Transvaginal Ultrasound: Endometrial Thickness

    Transvaginal ultrasounds were performed at Baseline (Week 0) and Week 52, or at the time of withdrawal in the case of a subject's premature discontinuation. Endometrial thickness, measured (double layer) in mm, were lesser than 4 mm for entry into the trial.

    Time frame: Week 0, week 52

07

Results

Posted Apr 7, 2011
Limitations and caveats
This was a single-arm, 12-month, open label, multicentre trial; therefore there were no comparator results available.

Participant flow

40 sites in Czech Republic, Denmark, Finland, France, Hungary, Norway, and Sweden

Participant flow — Overall Study
MilestoneVagifem® 10 mcg
Started336
Completed292
Not completed44

Outcome measures

PrimaryEndometrial Hyperplasia Based on Histological Assessment of Endometrial Biopsies

The endometrial hyperplasia rate was calculated based on the number of patients with endometrial hyperplasia/endometrial carcinoma divided by the total number of subjects with interpretable biopsies at Week 52.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Endometrial Hyperplasia Based on Histological Assessment of Endometrial Biopsies
percentage of participantsVagifem® 10 mcg
Simple hyperplasia without atypia0
Simple hyperplasia with atypia0
Complex hyperplasia without atypia0
Complex hyperplasia with atypia0
Carcinoma0
SecondaryTransvaginal Ultrasound: Endometrial Thickness

Transvaginal ultrasounds were performed at Baseline (Week 0) and Week 52, or at the time of withdrawal in the case of a subject's premature discontinuation. Endometrial thickness, measured (double layer) in mm, were lesser than 4 mm for entry into the trial.

Time frame:
Week 0, week 52
Reported as:
Mean · mm
Transvaginal Ultrasound: Endometrial Thickness
mmVagifem® 10 mcg
Baseline2.04 ± 0.9
Week 521.94 ± 0.9

Adverse events

Collected over Adverse events were collected over a time frame of 12 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Vagifem® 10 mcg—14/336 (4.2%)17/336 (5.1%)
Most frequent serious events
Showing 10 of 14
Most frequent serious events
EventVagifem® 10 mcg
Radius fractureInjury, poisoning and procedural complications2/336
Myocardial infarctionCardiac disorders1/336
Abdominal painGastrointestinal disorders1/336
MelaenaGastrointestinal disorders1/336
CholelithiasisHepatobiliary disorders1/336
Forearm fractureInjury, poisoning and procedural complications1/336
Post procedural haematomaInjury, poisoning and procedural complications1/336
Spinal column stenosisMusculoskeletal and connective tissue disorders1/336
Colon adenomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/336
Leukaemia recurrentNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/336
Most frequent other events
Most frequent other events
EventVagifem® 10 mcg
NasopharyngitisInfections and infestations17/336

Baseline characteristics

Age, Continuous
Age, Continuous(years)Vagifem® 10 mcg
Mean59.5 ± 6.2
Sex: Female, Male
Sex: Female, Male(Participants)Vagifem® 10 mcg
Female336
Male0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Vagifem® 10 mcg
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American0
White296
More than one race0
Unknown or Not Reported39
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)Vagifem® 10 mcg
Mean24.6 ± 3.4
08

Study locations

42 sites
  • Novo Nordisk Investigational Site
    Brno, 602 00, Czech Republic
  • Novo Nordisk Investigational Site
    Brno, 603 00, Czech Republic
  • Novo Nordisk Investigational Site
    Olomouc, 779 00, Czech Republic
  • Novo Nordisk Investigational Site
    Prague 5, 150 00, Czech Republic
  • Novo Nordisk Investigational Site
    Prague, 128 00, Czech Republic
  • Novo Nordisk Investigational Site
    Glostrup, 2600, Denmark
  • Novo Nordisk Investigational Site
    Herlev, 2730, Denmark
  • Novo Nordisk Investigational Site
    Hillerød, 3400, Denmark
  • Novo Nordisk Investigational Site
    Roskilde, 4000, Denmark
  • Novo Nordisk Investigational Site
    Virum, 2830, Denmark
  • Novo Nordisk Investigational Site
    Århus N, 8200, Denmark
  • Novo Nordisk Investigational Site
    Espoo, 02100, Finland
  • Novo Nordisk Investigational Site
    Kuopio, 70100, Finland
  • Novo Nordisk Investigational Site
    Oulu, 90100, Finland
  • Novo Nordisk Investigational Site
    Tampere, 33101, Finland
  • Novo Nordisk Investigational Site
    Turku, 20100, Finland
  • Novo Nordisk Investigational Site
    Evry, 91000, France
  • Novo Nordisk Investigational Site
    NANTES Cedex 1, 44093, France
  • Novo Nordisk Investigational Site
    Nimes, 30006, France
  • Novo Nordisk Investigational Site
    Paris, 75005, France
  • Novo Nordisk Investigational Site
    Paris, 75015, France
  • Novo Nordisk Investigational Site
    Paris, 75017, France
  • Novo Nordisk Investigational Site
    Budapest, H-1034, Hungary
  • Novo Nordisk Investigational Site
    Budapest, H-1088, Hungary
  • Novo Nordisk Investigational Site
    Budapest, H-1096, Hungary
  • Novo Nordisk Investigational Site
    Pecs, H-7624, Hungary
  • Novo Nordisk Investigational Site
    Szeged, H-6725, Hungary
  • Novo Nordisk Investigational Site
    Drammen, 3015, Norway
  • Novo Nordisk Investigational Site
    Hamar, NO-2317, Norway
  • Novo Nordisk Investigational Site
    Larvik, Norway
  • Novo Nordisk Investigational Site
    Oslo, 0264, Norway
  • Novo Nordisk Investigational Site
    Sandvika, NO-1337, Norway
  • Novo Nordisk Investigational Site
    Ski, NO-1400, Norway
  • Novo Nordisk Investigational Site
    Stavanger, NO-4011, Norway
  • Novo Nordisk Investigational Site
    Stavanger, NO-4020, Norway
  • Novo Nordisk Investigational Site
    Trondheim, NO-7012, Norway
  • Novo Nordisk Investigational Site
    Göteborg, 411 19, Sweden
  • Novo Nordisk Investigational Site
    Göteborg, 416 85, Sweden
  • Novo Nordisk Investigational Site
    Linköping, 582 22, Sweden
  • Novo Nordisk Investigational Site
    Malmö, 217 44, Sweden
  • Novo Nordisk Investigational Site
    Norrköping, 602 32, Sweden
  • Novo Nordisk Investigational Site
    Uppsala, 751 85, Sweden
09

References and documents

Publications

  • Simon J, Nachtigall L, Ulrich LG, Eugster-Hausmann M, Gut R. Endometrial safety of ultra-low-dose estradiol vaginal tablets. Obstet Gynecol. 2010 Oct;116(4):876-883. doi: 10.1097/AOG.0b013e3181f386bb. PubMed 20859151 ↗
  • Simon J, Nachtigall L, Gut R, Lang E, Archer DF, Utian W. Effective treatment of vaginal atrophy with an ultra-low-dose estradiol vaginal tablet. Obstet Gynecol. 2008 Nov;112(5):1053-60. doi: 10.1097/AOG.0b013e31818aa7c3. Erratum In: Obstet Gynecol. 2008 Dec;112(6):1392. PubMed 18978105 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2007, a primary completion of Nov 2008 and a completion of Nov 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2011, 2 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 2, 2007
First posted
Feb 5, 2007
Start
Jan 2007
Primary completionActual
Nov 2008
CompletionActual
Nov 2008
Results first posted
Apr 7, 2011
Last update
Mar 15, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 15, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00431132
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Feb 5, 2007
Start date
Jan 2007
Primary completion
Nov 2008
Completion
Nov 2008
Results posted
Apr 7, 2011
Last update
Mar 15, 2017

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Estradiol

Start the discussion